×
About 14,880 results
Men With BRCA2 Should Be Screened for Prostate Cancer
https://www.medscape.com/viewarticle/921000
Medscape Davenport L

Nov 7th, 2019 - Men who carry the BRCA2 gene mutation, which is linked to breast and ovarian cancer, are at risk of developing aggressive prostate cancer and so should undergo regular prostate-specific antigen (PSA) testing, suggest findings from a major study.

Three Leading National Public Health Organizations Ring The Alarm About All-time Highs Of STDs
http://www.ncsddc.org/three-leading-national-public-health-organizations-ring-the-alarm-about-all-time-highs-of-stds/

Oct 7th, 2019 - Data released this week by the Centers for Disease Control and Prevention (CDC) show STDs have surged for the fifth consecutive year, reaching an all-time high in the U.S. These dangerous trends in chlamydia, gonorrhea, and syphilis show no sign of slowing and affect millions of lives each year in the United States. Particularly worrisome is the emerging trend of newborn syphilis (congenital sy...

Genetics of Prostate Cancer (PDQ®)–Health Professional Version
https://www.cancer.gov/types/prostate/hp/prostate-genetics-pdq

Oct 4th, 2019 - This executive summary reviews the topics covered in this PDQ summary on the genetics of prostate cancer, with hyperlinks to detailed sections below that describe the evidence on each topic.

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Niraparib for the Treatment of Metastatic Castration-Resistant Prostate Cancer
https://www.jnj.com/janssen-announces-u-s-fda-breakthrough-therapy-designation-granted-for-niraparib-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer

Oct 2nd, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for niraparib, an orally-administered poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with BRCA1/2 gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have received prior taxane che...

U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
https://www.janssen.com/us-fda-approves-supplemental-new-drug-application-snda-erleada-apalutamide-treatment-patients

Sep 16th, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved ERLEADA® (apalutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).1 Today's approval follows FDA Priority Review Designation of the supplemental New Drug Application (sNDA) that was submitted in April 2019 and rev...

Urinary Incontinence in Women: Evaluation and Management
https://www.aafp.org/afp/2019/0915/p339.html
American Family Physician;

Sep 14th, 2019 - Urinary incontinence is a common problem among women worldwide, resulting in a substantial economic burden and decreased quality of life. The Women's Preventive Services Initiative is the only major organization that recommends annual screening for urinary incontinence in all women despite low to insufficient evidence regarding effectiveness and accuracy of methods. No other major organization ...

FDA approves darolutamide for non-metastatic castration-resistant prostate cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-darolutamide-non-metastatic-castration-resistant-prostate-cancer

Jul 28th, 2019 - On July 30, 2019, the Food and Drug Administration approved darolutamide (NUBEQA, Bayer HealthCare Pharmaceuticals Inc.) for non-metastatic castration-resistant prostate cancer. Approval was based on ARAMIS (NCT02200614), a multicenter, double-blind, placebo-controlled clinical trial in 1,509 patients with non-metastatic castration resistant prostate cancer. Patients were randomized (2:1) to...

Bladder Cancer
https://www.cancer.org/cancer/bladder-cancer.html

Jul 28th, 2019 - "Whether you (or a loved one) are worried about developing bladder cancer, have just been diagnosed, are going through treatment, or are trying to stay well after treatment, this detailed guide can help you find the answers you need.

FDA grants orphan drug designation to Imfinzi for small cell lung cancer
https://www.healio.com/hematology-oncology/lung-cancer/news/online/%7B1a3bbdcb-d89d-41b5-ba26-640b5acd5ee1%7D/fda-grants-orphan-drug-designation-to-imfinzi-for-small-cell-lung-cancer

Jul 11th, 2019 - The FDA granted orphan drug designation to durvalumab for the treatment of small cell lung cancer. Durvalumab (Imfinzi, AstraZeneca) — a human monoclonal antibody that binds to PD-L1 — already is approved in the United States for treatment of patients with unresectable, stage III non-small cell lung cancer who underwent chemotherapy and radiation. The agent also is approved for previously tr...

Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2737101
JAMA Network Open;

Jul 2nd, 2019 - Question Is androgen deprivation therapy exposure associated with dementia among elderly patients with prostate cancer? Findings In this cohort study of 154 089 elderly men with prostate cancer, androgen deprivation therapy exposure was associated with subsequent diagnosis of Alzheimer disease or dementia over a follow-up period of at least 10 years. Meaning Clinicians must carefully w...

PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes
https://jnccn.org/view/journals/jnccn/17/7/article-p795.xml

Jun 30th, 2019 - Background: Most patients with prostate cancer are diagnosed with low-grade, localized disease and may not require definitive treatment. In 2012, the U.S. Preventive Services Task Force (USPSTF) recommended against prostate cancer screening to address overdetection and overtreatment. This study sought to determine the effect of guideline changes on prostate-specific antigen (PSA) screening and ...

Retrophin Announces FDA Approval of THIOLA® EC (tiopronin) 100mg and 300mg Tablets for the Treatment of Cystinuria
http://ir.retrophin.com/news-releases/news-release-details/retrophin-announces-fda-approval-thiolar-ec-tiopronin-100mg-and

Jun 27th, 2019 - Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S. Food and Drug Administration (FDA) has approved 100 mg and 300 mg tablets of THIOLA® EC (tiopronin), a new enteric-coated formulation of THIOLA® (tiopronin), to be used for the treatment of cystinuria, a rare inherited disorder that causes a buildup of cystine levels in the urine resulting in the formation of recurring cystine kidney...

Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade
http://mcr.aacrjournals.org/content/early/2019/06/18/1541-7786.MCR-19-0115
Gong, Y. et. al.

Jun 19th, 2019 - An excess incidence of prostate cancer has been identified among World Trade Center (WTC) responders. In this study, we hypothesized that WTC dust, which contained carcinogens and tumor-promoting agents, could facilitate prostate cancer development by inducing DNA damage, promoting cell proliferation, and causing chronic inflammation. We compared expression of immunologic and inflammatory genes...

NICE Guidance – Prostate cancer: diagnosis and management
https://onlinelibrary.wiley.com/doi/10.1111/bju.14809

Jun 16th, 2019 - This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow‐up in primary care for people diagnosed with prostate cancer.

Testosterone - Lab Test
https://labtestsonline.org/tests/testosterone

Jun 4th, 2019 - Why Get Tested? To detect an abnormal testosterone level in males and females; in males, to help diagnose the cause of erectile dysfunction or the inability of your partner to get pregnant (infertility); in females, to help diagnose the cause of masculine physical features (virilization), infertility, or polycystic ovary syndrome (PCOS); in children, to help determine the cause of genitals tha...

FDA clears first diagnostic tests for extragenital testing for chlamydia and gonorrhea
https://www.fda.gov/news-events/press-announcements/fda-clears-first-diagnostic-tests-extragenital-testing-chlamydia-and-gonorrhea

May 22nd, 2019 - Today, the U.S. Food and Drug Administration cleared for marketing two tests that can detect the presence of the bacteria Chlamydia trachomatis and Neisseria gonorrhoeae, which cause the sexually-transmitted infections, respectively, chlamydia and gonorrhea, through diagnostic testing of extragenital specimens. The Aptima Combo 2 Assay and the Xpert CT/NG are the first devices cleared for extra...

Infertility Workup for the Women’s Health Specialist
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/Infertility-Workup-for-the-Womens-Health-Specialist

May 22nd, 2019 - ABSTRACT: Infertility, defined as failure to achieve pregnancy within 12 months of unprotected intercourse or therapeutic donor insemination in women younger than 35 years or within 6 months in women older than 35 years, affects up to 15% of couples. An infertility evaluation may be offered to any patient who by definition has infertility or is at high risk of infertility. Women older than 35 y...

A four‐group urine risk classifier for predicting outcomes in patients with prostate cancer
https://onlinelibrary.wiley.com/doi/10.1111/bju.14811
BJU International; Connell, S. et. al.

May 19th, 2019 - To develop a risk classifier using urine‐derived extracellular vesicle (EV)‐RNA capable of providing diagnostic information on disease status prior to biopsy, and prognostic information for men on active surveillance (AS). Patients and Methods Post‐digital rectal examination urine‐derived EV‐RNA expression profiles (n = 535, multiple centres) were interrogated with a curated NanoString pane...

Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline
https://www.auanet.org/guidelines/recurrent-uti

Apr 30th, 2019 - Over the past few decades, our ability to diagnose, treat, and manage recurrent urinary tract infection (rUTI) long-term has evolved due to additional insights into the pathophysiology of rUTI, a new appreciation for the adverse effects of repetitive antimicrobial therapy (“collateral damage”), rising rates of bacterial antimicrobial resistance, and better reporting of the natural history and c...

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
https://jnccn.org/view/journals/jnccn/17/5/article-p479.xml
Journal of the National Comprehensive Cancer Network;

Apr 30th, 2019 - An estimated 174,650 new cases of prostate cancer will be diagnosed in 2019, accounting for 20% of new cancer cases in men.1 The age-adjusted death rates from prostate cancer have declined 51% from 1993 to 2016.1 Researchers have estimated that prostate cancer will account for 9.8% of male cancer deaths in 2018.1 Over the past several years, the incidence of prostate cancer has declined, likely...